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Introduction: Bevacizumab when combined with carboplatin and
paclitaxel improves response rates (RRs) and overall survival in
patients with advanced non-small cell lung cancer. Paclitaxel has
single-agent activity in relapsed small cell lung cancer (SCLC).
Angiogenesis seems to play an important role in the pathogenesis of
SCLC. This study evaluated the safety and efficacy of paclitaxel plus
bevacizumab in patients with chemosensitive relapsed SCLC.
Methods: Patients with relapsed chemosensitive SCLC with an
Eastern Cooperative Oncology Group performance status of 0 to 1
were eligible. They received paclitaxel 90 mg/m2 intravenously on
days 1, 8, and 15. Bevacizumab was administered at 10 mg/kg
intravenously on days 1 and 15. Cycles were every 28 days. The
primary endpoint was progression-free survival (PFS). Secondary
endpoints included RRs, toxicity, and overall survival. Correlative
studies evaluated vascular endothelial growth factor polymorphisms.
Results: Thirty-four patients were enrolled in the study. Median age
was 66.5 (range, 38–88) years, male:female: 61.8%:38.2%, Eastern
Cooperative Oncology Group performance status 0:1 47.1%:52.9%.
Median progression-free survival was 14.7 weeks (equivalent to
historical controls). Median survival time was 30 weeks. The overall
RR was 18.1%. Stable disease rate was 39.3%, and 45.4% of
patients had progressive disease. No unexpected toxicities were
noted, and grade 3/4 toxicities were limited to neutropenia, fatigue,
and dyspnea. None of the vascular endothelial growth factor poly-
morphisms evaluated were significantly associated with response.
Conclusions: The addition of bevacizumab to paclitaxel does not
improve outcomes in relapsed chemosensitive SCLC.
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Small cell lung cancer (SCLC) accounts for 13 to 15% oflung cancers with the majority of patients ultimately
succumbing to their disease.1 The majority of patients are
diagnosed with extensive disease at presentation and are
treated with platinum-based therapy. Depending on the dura-
tion of response to platinum-based therapy, patients are
described as having chemosensitive or chemorefractory dis-
ease. Those with chemosensitive disease, typically defined as
relapsing more than 60 to 90 days after completion of
platinum-based therapy, frequently benefit from further che-
motherapy at the time of disease progression. Multiple agents
have activity in the second-line setting, but responses are
typically brief (2–4 months), and survival times are short
(median, 6 months). Paclitaxel also has single-agent activity
in chemotherapy-naive patients with SCLC with a response
rate (RR) of 30 to 50%.2,3 In addition, paclitaxel is active in
a chemorefractory population with SCLC.4
Bevacizumab (Avastin, Genentech, South San Fran-
cisco, CA) is a recombinant vascular endothelial growth
factor (VEGF) monoclonal antibody that was included in the
first-line treatment paradigm of advanced non-small cell lung
cancer after its combination with carboplatin/paclitaxel in the
Eastern Cooperative Oncology Group (ECOG) 4599 study.
This trial showed an improvement in RR and overall survival
(OS) compared with chemotherapy alone.5
SCLC is a tumor with early hematogenous spread.
Tumor microvessel count and VEGF expression were prog-
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nostic factors and correlated with worse survival (p  0.001
and p  0.0008, respectively) in patients with SCLC who
underwent pneumonectomies or lobectomies.6 VEGF was
also reported to be expressed in 81% of patients with SCLC.7
Therefore, we initiated this study evaluating the safety
and efficacy of the combination of paclitaxel and bevaci-
zumab in relapsed chemosensitive SCLC. We used the dosing
schedule evaluated as initial treatment in patients with met-
astatic breast cancer in which the combination resulted in an
improvement in RR (36.9% versus 21.2%, p  0.001) and
progression-free survival (PFS; 11.8 versus 5.9 months, haz-
ard ratio  0.6, p  0.001) over paclitaxel alone.8
PATIENTS AND METHODS
Eligibility criteria included age 18 years, histo-
logic or cytologic diagnosis of SCLC, prior treatment with
at least one platinum-containing regimen, ECOG perfor-
mance status 0 to 1, and measurable disease by Response
Evaluation Criteria in Solid Tumor (RECIST) Group re-
sponse criteria. All patients had chemosensitive disease
defined as relapse more than 60 days after completing
initial treatment. Adequate hematologic, renal, and liver
function at baseline were required. No therapies were
allowed within 3 weeks of registration. Patients were
excluded if they had evidence of brain metastases within
42 days of registration. All patients provided written
informed consent before enrolling in the study. Local
institutional review boards approved the protocol.
Treatment Plan
Patients received 90 mg/m2 of paclitaxel as a 1-hour
intravenous infusion on days 1, 8, and 15 and bevacizumab at
10 mg/kg intravenously on days 1 and 15. Cycles were
repeated every 28 days. Patients were premedicated before
paclitaxel per package insert. Bevacizumab was administered
after the completion of paclitaxel on day 1 of cycle 1. After
4 to 6 cycles of treatment with the combination, patients were
allowed to continue with bevacizumab alone as maintenance
therapy until disease progression or intolerable side effects.
Statistical Analysis
The primary endpoint of the study was PFS defined as
the interval from the start of therapy until disease progression
or death. Secondary endpoints included RR as defined by the
Response Evaluation Criteria in Solid Tumor criteria and OS
time defined as time from initiation of first cycle to death.
Other secondary endpoints included determination of adverse
events, their severity, and all grade 3 and grade 4 toxicities.
The median PFS with historical controls (topotecan) is
14 weeks. With a total number of 34 patients, this study had
91% power and   5%, to detect an improvement in PFS to
24 weeks.
Laboratory Correlates
Correlative studies involved evaluation of VEGF
polymorphisms and their correlation with RR. Fisher’s
exact test was used to correlate VEGF polymorphisms with
response data.
Blood samples were collected in 6-mL lavender-top
tubes from patients agreeable to laboratory correlatives. The
following VEGF polymorphisms were evaluated: 936 C/T,
634 G/C, 2578 C/A, 1154 G/A, and 460 C/T. These
specific polymorphisms were selected because of their known
impact on modulating angiogenesis. Polymorphisms were
assessed using standard polymerase chain-restriction frag-
ment length polymorphism methods that are previously es-
tablished and Taqman-based assays.9
RESULTS
Between April 26, 2006, and January 11, 2007, 34
patients were enrolled in the study. Baseline characteristics
are summarized in Table 1.
Treatment Administered (n  33)
The median number of cycles received on trial was 3
(range, 1–9). Approximately 60% of patients were able to
receive the study regimen without dose modifications. Fifty
percent of the patients required no dose delays. Only two
patients continued on the maintenance bevacizumab phase
after six cycles of paclitaxel plus bevacizumab.
Efficacy
Response results are available for 33 patients because
one patient never received treatment. One complete response
(CR) was observed, five patients achieved a partial response
(PR) (15.1%) for an overall RR of 18.1%. Fifteen patients
progressed (45.4%), and stable disease was noted in 13
patients (39.3%). The median PFS was 14.7 weeks (95%
confidence interval  7–15.7), and the median survival time
(MST) was 30 weeks (95% confidence interval  18–48).
TABLE 1. Baseline Characteristics (n  34)
Characteristics n  34
Age (yr)
Median 66.5
Range 38–88
Sex, n (%)
Male 21 (61.8)
Female 13 (38.2)
ECOG PS
0 16 (47.1)
1 18 (52.9)
Smoking history, n (%)
Current 12 (35.3)
Former 20 (58.8)
Never 2 (5.9)
Prior treatment, n (%)
1. Chemotherapy 29 (85.3)
2. Chemotherapy 5 (14.7)
Radiotherapy 18 (31)
Median number of days from previous regimen to
registration (range)
142 (35–557)
ECOG PS, Eastern cooperative oncology group performance status.
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Safety/Toxicity
Toxicities noted in 10% of patients (n  34) are
presented in Tables 2 and 3. No unexpected toxicities were
observed with the combination. Grade 1 pulmonary hemor-
rhage was noted in one patient. Three patients had grade 1 to
grade 2 proteinuria. There were no febrile neutropenia epi-
sodes and no treatment-related deaths.
Laboratory Correlative Results
Data were available for 30 patients to assess VEGF
polymorphisms and association with response. The frequen-
cies of the various VEGF polymorphisms in different patient
response groups are presented in Table 4. No associations
were statistically significant, although the association of
VEGF 1154GA with response approached statistical signifi-
cance (p  0.0677).
DISCUSSION
The addition of bevacizumab to paclitaxel does not
seem to improve PFS in patients with chemosensitive re-
lapsed SCLC. The median PFS reported with this combina-
tion is similar to that reported with topotecan. In addition, the
RR of 18.1% is similar to that of other regimens, and the
MST was 7.5 months. The regimen seems safe, and no
unexpected toxicities were observed.
Our study yielded comparable results with another
phase II study, which combined topotecan with bevaci-
zumab.10 That trial included both chemosensitive and che-
morefractory patients, was associated with more grade 3 to
grade 4 toxicities, and reported a MST and PFS of only 32
and 18.4 weeks, respectively.
Other studies have evaluated bevacizumab combined
with chemotherapy in previously untreated patients with
SCLC. ECOG conducted a phase II trial that evaluated the
addition of bevacizumab to cisplatin and etoposide. The
combination was tolerable with no unexpected toxicities, but
efficacy was not substantially different than expected with
cisplatin plus etoposide alone.11 The Cancer and Leukemia
Group B evaluated the combination of cisplatin and irinote-
can plus bevacizumab in 68 untreated patients with extensive
stage SCLC.12 Median PFS was 7.1 months, and MST was
11.7 months. These results compared favorably with out-
comes from other trials, but the study failed to reach its
primary endpoint of improving survival times compared with
historical controls.13 The Sara Cannon group evaluated bev-
acizumab combined with carboplatin and irinotecan in a
similar patient population. The median time to disease pro-
gression was 9.1 months, and MST was 12.1 months.14
Nevertheless, this regimen was associated with a significant
incidence of grade 3 or more diarrhea and fatigue.
Collectively, this data suggest that bevacizumab is
unlikely to substantially improve outcomes in unselected
patients with SCLC. Our study also investigated whether
subgroups of patients with certain VEGF polymorphisms
may preferentially benefit from bevacizumab. Schneider et
al.15 were the first to describe VEGF polymorphisms that
correlate with efficacy and toxicity with bevacizumab in
patients with metastatic breast cancer. In their analysis,
TABLE 2. Hematologic Toxicities (n  34)
Toxicity Any Grade, n (%) Grades 3–4, n (%)
Hematologic
Neutropenia 9 (26) 6 (17.6)
Febrile neutropenia 0 0
Anemia 12 (35) 0
Thrombocytopenia 6 (17.6) 0
TABLE 3. Nonhematologic Toxicities (n  34)
Toxicity
Any Grade,
n (%)
Grades 3–4,
n (%)
Fatigue 29 (85) 9 (26)
Dyspnea 20 (58.8) 5 (14.7)
Hypertension 9 (26.4) 0
Neuropathy 15 (44) 0
Nausea 17 (50) 0
Vomiting 4 (11.7) 0
Liver enzyme abnormalities
Elevation in alkaline phosphatase 5 (14.7) 0
Elevation in AST 5 (14.7) 0
Diarrhea 12 (35) 0
Constipation 17 (50) 0
Anorexia 19 (55.8) 0
Mucositis 6 (17.6) 0
Hyperglycemia 5 (14.7) 0
Headache 11 (32.3) 0
AST, aspartate aminotransferase.
TABLE 4. Frequencies of VEGF Polymorphisms and
Correlation with Responses (n  30)
VEGF Polymorphism CR/PR (%) PD (%) SD (%)
VEGF-2578
AA 2 (6.6) 3 (10) 1 (3.3)
CA 3 (10) 5 (16.7) 5 (16.7)
CC 0 (0) 2 (6.6) 6 (20)
VEGF-1154
AA 0 (0) 1 (3.3) 0 (0)
GA 5 (16.7) 6 (20) 4 (13.3)
GG 0 (0) 6 (20) 8 (26.6)
VEGF 936
CC 3 (10) 10 (33.3) 10 (33.3)
CT 1 (3.3) 3 (10) 1 (3.3)
TT 1 (3.3) 0 (0) 1 (3.3)
VEGF-634
CC 0 (0) 4 (13.3) 2 (6.6)
GC 3 (10) 2 (6.6) 4 (13.3)
GG 2 (6.6) 7 (23.3) 6 (20)
VEGF-1498
CC 2 (6.6) 3 (10) 1 (3.3)
CT 3 (10) 6 (20) 5 (16.7)
TT 0 (0) 4 (13.3) 6 (20)
VEGF, vascular endothelial growth factor; SD, stable disease; PD, progressive
disease; CR, complete response; PR, partial response.
Jalal et al. Journal of Thoracic Oncology • Volume 5, Number 12, December 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer2010
VEGF-2578 AA and VEGF-1154 AA genotypes correlated
with a superior median OS with a bevacizumab-containing
regimen in advanced breast cancer. In this analysis, VEGF-
634 CC and VEGF-1498 TT genotypes were associated with
a decreased risk of significant hypertension with bevaci-
zumab. This study is the first to evaluate VEGF polymor-
phisms in SCLC. We were unable to identify a VEGF
polymorphism that was associated with response. Neverthe-
less, interpretation of VEGF polymorphisms and their impact
on response in our study should be viewed with caution due
to the small patient number, the even smaller patient number
in different response subgroups, and the lack of grade 3 to
grade 4 hypertension, a potential surrogate for benefit with
VEGF-directed therapy. Furthermore, multiple association
tests were performed; therefore, the traditional p value less
than 0.05 for statistical significance may not be valid.
Patients with relapsed SCLC continue to be in need of
improved therapy options. Continued understanding of the
complex biology of this smoking-associated illness confirms
the differences between SCLC and non-small cell lung cancer
where multiple agents of benefit in the latter are ineffective in
SCLC. Chemotherapy remains the cornerstone of therapy for
patients with SCLC.
Novel therapies and strategies in the treatment of this
disease continue to be explored.
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